Testing for acute HIV infection: Implications for treatment as prevention

Current Opinion in HIV and AIDS

Volumn 7, Issue 2, 2012, Pages 125-130

  Owen, S M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

acute infection; diagnostics; HIV; preexposure prophylaxis; prevention

Indexed keywords

ALGORITHM; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; VIRUS DIAGNOSIS; VIRUS TRANSMISSION;

AIDS SERODIAGNOSIS; ALGORITHMS; ANTI-HIV AGENTS; FEMALE; HIV ANTIBODIES; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; MALE; NUCLEIC ACID AMPLIFICATION TECHNIQUES;

EID: 84857356224     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283506613     Document Type: Review

References (75)

1. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS cohort study investigators. JAMA 1998; 280:1497-1503. (Pubitemid 28507402)
2. McNaghten AD, Hanson DL, Jones JL, et al. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. AIDS 1999; 13:1687-1695. (Pubitemid 30015716)
3. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730. (Pubitemid 28534954)
4. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11-19.
5. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr 2005; 39:446-453. (Pubitemid 41003791)
6. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 2006; 20:1447-1450. (Pubitemid 43948252)
7. Metsch LR, Pereyra M, Messinger S, et al. HIV transmission risk behaviors among HIV-infected persons who are successfully linked to care. Clin Infect Dis 2008; 47:577-584.
8. Smith K, Powers KA, Kashuba AD, Cohen MS. HIV-1 treatment as prevention: the good, the bad, and the challenges. Curr Opin HIV AIDS 2011; 6:315-325. This is an extensive review article on test and treat as an HIV prevention approach. It highlights the pros, cons and challenges for using treatment as prevention
9. Parry JV, Mortimer PP, Perry KR, et al. Towards error-free HIV diagnosis: guidelines on laboratory practice. Commun Dis Public Health 2003; 6:334-350.
10. Branson BM. The future of HIV testing. J Acquir Immune Defic Syndr 2010; 55 (Suppl 2):S102-S105. This article highlights current and future HIV testing technology and practices.
11. Branson B. Conference wrap-up: unified laboratory algorithm 2010 HIV Diagnostics Conference; 24-26 March 2010; Orlando, FL. This is a meeting summary that highlights the key findings of the 2010 HIV diagnostics conference.
12. Cohen MS, Gay CL, Busch MP, Hecht FM. The detection of acute HIV infection. J Infect Dis 2010; 202 (Suppl 2):S270-S277. This is a comprehensive article that describes testing methodology and highlights the advantages for detecting AHIs.
13. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998; 339:33-39.
14. Hare CB, Kahn JO. Primary HIV Infection. Curr Infect Dis Rep 2004; 6:65-71. (Pubitemid 39345319)
15. Clinical and Laboratory Standards Institute (CLSI). Criteria for laboratory testing and diagnosis of human immunodeficiency virus infection; approved guideline; 2011. Document No. M53-A. This is a guideline document that explains the basic principles of HIV testing, as well as highlights the improved HIV testing algorithms for use in laboratory settings.
16. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991; 324:961-964.
17. Pilcher CD, Joaki G, Hoffman IF, et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 2007; 21:1723-1730. (Pubitemid 47237559)
18. Morrison CS, Demers K, Kwok C, et al. Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection. AIDS 2010; 24:573-582. This article describes the viral loads found in plasma and cervical fluids during acute infection. The work highlights the potential for increased transmission during acute infection.
19. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403-1409. (Pubitemid 40563350)
20. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008; 198:687-693.
21. Brenner BG, Roger M, Routy JP, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007; 195:951-959. (Pubitemid 46452099)
22. Ma ZM, Stone M, Piatak M Jr, et al. High specific infectivity of plasma virus from the preramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol 2009; 83:3288-3297.
23. Pilcher CD, Christopoulos KA, Golden M. Public health rationale for rapid nucleic acid or p24 antigen tests for HIV. J Infect Dis 2010; 201 (Suppl 1): S7-S15. This article describes current rapid testing options and highlights the potential advantages for rapid HIV antigen assays.
24. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 Infection. N Engl J Med 2011; 364:1943-1954. This is a comprehensive review of AHI. It describes virologic, immunologic and diagnostic aspects of AHI.
25. Powers KA, Ghani AC, Miller WC, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet 2011; 378:256-268. This is modeling study that predicts the value of detecting acute/early HIV infection as it relates to preventing further transmission.
26. Busch MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med 1997; 102 (5B):117-124; discussion 25-6. (Pubitemid 27334765)
27. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871-1879. (Pubitemid 37070272)
28. Owen SM, Yang C, Spira T, et al. Alternative algorithms for human immunodeficiency virus infection diagnosis using tests that are licensed in the United States. J Clin Microbiol 2008; 46:1588-1595. (Pubitemid 351657199)
29. Weber B, Gurtler L, Thorstensson R, et al. Multicenter evaluation of a new automated fourth-generation human immunodeficiency virus screening assay with a sensitive antigen detection module and high specificity. J Clin Microbiol 2002; 40:1938-1946. (Pubitemid 34596366)
30. Ly TD, Martin L, Daghfal D, et al. Seven human immunodeficiency virus (HIV) antigen-antibody combination assays: evaluation of HIV seroconversion sensitivity and subtype detection. J Clin Microbiol 2001; 39:3122-3128. (Pubitemid 32830303)
31. Ly TD, Laperche S, Brennan C, et al. Evaluation of the sensitivity and specificity of six HIV combined p24 antigen and antibody assays. J Virol Methods 2004; 122:185-194. (Pubitemid 39470190)
32. Weber B. Screening of HIV infection: role of molecular and immunological assays. Expert Rev Mol Diagn 2006; 6:399-411. (Pubitemid 44174344)
33. Murphy G, Aitken C. HIV testing-the perspective from across the pond. J Clin Virol 2011; 52, Supplement 1(0):S71-S76. This article describes the current HIV diagnostic testing methodology used in the United Kingdom and highlights the use of antigen/antibody assays as the initial (screening) HIV assay.
34. Ly TD, Ebel A, Faucher V, et al. Could the new HIV combined p24 antigen and antibody assays replace p24 antigen specific assays? J Virol Methods 2007; 143:86-94. (Pubitemid 46802829)
35. Layne SP, Merges MJ, Dembo M, et al. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology 1992; 189:695-714.
36. Pandori MW, Hackett J Jr, Louie B, et al. Assessment of the Ability of a Fourth Generation Immunoassay for HIV Antibody and p24 Antigen to Detect both Acute and Recent HIV Infection in a High-Risk Setting. J Clin Microbiol 2009; 47:2639-2642.
37. Chavez P, Wesolowski L, Patel P, et al. Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab Combo Assay. J Clin Virol 2011; 52, Supplement 1(0):S51-S55. This article describes the performance characteristics of the recently FDA approved Abbott Architect antigen/antibody assay.
38. Bentsen C, McLaughlin L, Mitchell E, et al. Performance evaluation of the Bio- Rad Laboratories GS HIV Combo Ag/Ab EIA, a 4th generation HIV assay for the simultaneous detection of HIV p24 antigen and antibodies to HIV-1 (groups M and O) and HIV-2 in human serum or plasma. J Clin Virol 2011; 52, Supplement 1(0):S57-S61. This article describes the performance characteristics of the recently FDA approved Bio-Rad antigen/antibody assay.
39. Masciotra S, McDougal JS, Feldman J, et al. Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. J Clin Virol 2011; 52, Supplement 1(0):S17-S22. This article describes and evaluates the recently proposed HIV laboratory-testing algorithm. Data in the study indicate that the proposed laboratory testing algorithm will detect a good proportion of AHIs.
40. Farnham PG, Hutchinson AB, Sansom SL, Branson BM. Comparing the costs of HIV screening strategies and technologies in health-care settings. Public Health Rep 2008; 123 (Suppl 3):51-62.
41. Heffelfinger J, Owen SM, Hendry RM, Lansky A. HIV testing: the cornerstone of HIV prevention efforts in the USA. Future Virol 2011; 6:1299-1317. This paper describes a very comprehensive review of HIV testing technology and testing practices. It highlights the importance of HIV testing in all HIV prevention efforts.
42. Stekler J, Wood RW, Swenson PD, Golden M. Negative rapid HIV antibody testing during early HIV infection. Annals of internal medicine 2007; 147: 147-148 (Pubitemid 351664627)
43. Delaney KP, Branson BM, Uniyal A, et al. Evaluation of the performance characteristics of 6 rapid HIV antibody tests. Clin Infect Dis 2011; 52:257-263. This article highlights the performance of the proposed laboratory HIV diagnostic testing algorithm and supports the implementation of the proposed testing algorithm.
44. Nasrullah M, Ethridge SF, Delaney KP, et al. Comparison of alternative interpretive criteria for the HIV-1 Western blot and results of the Multispot HIV-1/HIV-2 Rapid Test for classifying HIV-1 and HIV-2 infections. J clin virol 2011; 52, Supplement 1(0):S23-S27. This article examines the performance characteristics of two assays that are potential components of the recently proposed laboratory HIV testing algorithm.
45. Stekler JD, Swenson PD, Coombs RW, et al. HIV testing in a high-incidence population: is antibody testing alone good enough? Clin Infect Dis 2009; 49:444-453.
46. Fox J, Dunn H, O'Shea S. Low rates of p24 antigen detection using a fourthgeneration point of care HIV test. Sex Transm Infect 2011; 87:178-179. A description of the performance characteristics of a rapid antigen/antibody is the primary focus of this article.
47. Beelaert G, Fransen K. Evaluation of a rapid and simple fourth-generation HIV screening assay for qualitative detection of HIV p24 antigen and/or antibodies to HIV-1 and HIV-2. J Virol Methods 2010; 168 (1-2):218-222. Like reference 46, this article describes the test procedure and performance characteristics of a rapid antigen/antibody assay.
48. Parpia ZA, Elghanian R, Nabatiyan A, et al. p24 antigen rapid test for diagnosis of acute pediatric HIV infection. J Acquir Immune Defic Syndr 2010; 55:413-419. This article describes the test procedure and performance characteristics of an experimental rapid antigen/antibody assay.
49. Workman S, Wells SK, Pau CP, et al. Rapid detection of HIV-1 p24 antigen using magnetic immuno-chromatography (MICT). J Virol Methods 2009; 160 (1-2):14-21.
50. Patel P, Mackellar D, Simmons P, et al. Detecting acute human immunodeficiency virus infection using 3 different screening immunoassays and nucleic acid amplification testing for human immunodeficiency virus RNA, 2006- 2008. Arch Intern Med 2010; 170:66-74. The data presented in this article illustrate the utility of using NAAT and or Ag/Ab assays for detecting acute HIV.
51. Schito ML, D'Souza MP, Owen SM, Busch MP. Challenges for rapid molecular HIV diagnostics. J Infect Dis 2010; 201 (Suppl 1):S1-S6. The challenges for developing and validating rapid molecular HIV diagnostic tests are discussed in this article.
52. Curtis KA, Rudolph DL, Owen SM. Rapid detection of HIV-1 by reversetranscription, loop-mediated isothermal amplification (RT-LAMP). J Virol Methods 2008; 151:264-270.
53. Tang W, Chow WH, Li Y, et al. Nucleic acid assay system for tier II laboratories and moderately complex clinics to detect HIV in low-resource settings. J Infect Dis 2010; 201 (Suppl 1):S46-S51. This article describes an isothermal NAAT that could be performed in an area that does not have extensive laboratory equipment.
54. Lee HH, Dineva MA, Chua YL, et al. Simple amplification-based assay: a nucleic acid-based point-of-care platform for HIV-1 testing. J Infect Dis 2010; 201 (Suppl 1):S65-S72. This article describes an isothermal NAAT that has the potential to be used in POC settings to detect AHI.
55. Tanriverdi S, Chen L, Chen S. A rapid and automated sample-to-result HIV load test for near-patient application. J Infect Dis 2010; 201 (Suppl 1):S52-S58. This article describes a simple, rapid viral load test that would be useful for monitoring the efficacy of antiretroviral treatment.
56. Pau C P, Wells SK, Owen SM, Granade TC. Development of a simple, rapid and inexpensive method for the qualitative detection of HIV-1 RNA. Proceedings of the 2010 HIV Diagnostics Conference; 24-26 March 2010; Orlando, FL. http://www.hivtestingconference.org/posters.html.
57. Mazzola LT, Arsham AM, Pederson AM, et al. Innovative point-of-care HIV viral load detection in RLS. Proceedings of the 2010 HIV Diagnostics Conference; 2010; Orlando, FL. http://www.hivtestingconference.org/posters.html.
58. Centers for Disease Control and Prevention. Interpretation and use of the western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR Morb Mortal Wkly Rep 1989; 38 (Suppl 7):1-7.
59. Wesolowski LG, Delaney KP, Hart C, et al. Performance of an alternative laboratory-based algorithm for diagnosis of HIV infection utilizing a third generation immunoassay, a rapid HIV-1/HIV-2 differentiation test and a DNA or RNA-based nucleic acid amplification test in persons with established HIV-1 infection and blood donors. J Clin Virol 2011; 52, Supplement 1(0):S45-S49. This article shows that the performance of the recently proposed diagnostic algorithm is comparable with the current diagnostic algorithm that utilizes western blotting for a population of individuals with known established HIV infection.
60. Delaney KP, Heffelfinger JD, Wesolowski LG, et al. Performance of an alternative laboratory-based algorithm for HIV diagnosis in a high-risk population. J Clin Virol 2011; 52, Supplement 1(0):S5-S10. The recently proposed diagnostic algorithm is examined in this body of work. The findings from this high-risk population indicate that the proposed algorithm functions well in high-risk populations.
61. Torian LV, Forgione LA, Punsalang AE, et al. Comparison of Multispot EIA with Western blot for confirmatory serodiagnosis of HIV. J Clin Virol 2011; 52, Supplement 1(0):S41-S44. This is another article that examines the performance of two different assays in the proposed HIV laboratory diagnostic algorithm.
62. Styer LM, Sullivan TJ, Parker MM. Evaluation of an alternative supplemental testing strategy for HIV diagnosis by retrospective analysis of clinical HIV testing data. J Clin Virol 2011; 52, Supplement 1(0):S35-S40. This work describes the performance of the proposed laboratory-testing algorithm in New York State and supports the implementation of the new laboratory testing algorithm.
63. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55 (RR-14):1-17.
64. Fiscus SA, Pilcher CD, Miller WC, et al. Rapid, real-time detection of acute HIV infection in patients in Africa. J Infect Dis 2007; 195:416-424. (Pubitemid 46146120)
65. Pilcher CD, Fiscus SA, Nguyen TQ, et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med 2005; 352:1873-1883. (Pubitemid 40627813)
66. Priddy FH, Pilcher CD, Moore RH, et al. Detection of acute HIV infections in an urban HIV counseling and testing population in the United States. J Acquir Immune Defic Syndr 2007; 44:196-202. (Pubitemid 46292223)
67. Patel P, Klausner JD, Bacon OM, et al. Detection of acute HIV infections in high-risk patients in California. J Acquir Immune Defic Syndr 2006; 42:75-79. (Pubitemid 43947949)
68. Acute HIV infection: New York City, 2008. Morb Mortal Wkly Rep 2009; 58:1296-1299.
69. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174. The performance of a gel that contains tenofovir as an HIV prevention tool is described in this article. The work is one of four studies that indicates that PrEP may be an effective prevention tool.
70. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599. Like reference [69&& ] this article describes the successful use of PrEP as an HIV prevention tool. In this study, oral PrEP was used in a population of MSM.
71. Conference Summary Report on the 6th IAS Conference on HIV pathogenesis, treatment and prevention (IAS 2011): research highlights and implications for policy and practice. Proceedings of the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 17-20 July 2011; Rome Italy. http://www.iasociety.org/ Web/WebContent/File/IAS2011-Conference-Report.pdf. This article is a meeting summary of the latest IAS meeting and, within the document, two of the most recent PrEP success stories are described.
72. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505. This is a groundbreaking study that demonstrated that early retroviral treatment of infected individuals can serve as a tool for preventing onward transmission of HIV-1.
73. Cohen MS, Gay CL. Treatment to prevent transmission of HIV-1. Clin Infect Dis 2010; 50 (Suppl 3):S85-S95.
74. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
75. Walensky RP, Paltiel AD, Losina E, et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis 2010; 51:392-400.